Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.
Metrics to compare | GNCAQ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGNCAQPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −3.3x | −0.6x | |
PEG Ratio | 0.00 | 0.27 | 0.00 | |
Price/Book | 0.0x | 2.9x | 2.6x | |
Price / LTM Sales | 0.0x | 30.2x | 3.2x | |
Upside (Analyst Target) | 0.0% | 137.4% | 44.1% | |
Fair Value Upside | Unlock | 1.2% | 6.2% | Unlock |